Monday, October 12, 2015

Avadim Technologies delivers record third quarter 2015 gross revenue

Avadim Technologies, Inc. (“Avadim”), a life sciences company focused on developing pathways to address emerging gaps in global health, announced today record-breaking revenue results for its third quarter 2015. The Company reported consolidated unaudited gross revenue of approximately $1,268,000, which was up 157% over the third quarter 2014 of $493,000. The Company also reported 2015 third quarter revenue increase 45% over second quarter 2015 of $874,000.

Steve Woody, Chairman and CEO of Avadim, said, “We are very pleased that our third quarter results were as expected. Our relentless pace of growth is driven by our proven strategy of serving our customers and stakeholders through innovation of our expanding pathogenesis based therapy platform. We are well-positioned to continue to deliver long-term growth.”

The quarterly estimated gross revenue presented in this release are based on preliminary financial data and are subject to change until the year-end financial reporting process is completed.
About Avadim Technologies, Inc.
Avadim Technologies, Inc. is a life sciences company that has developed a series of Pathogenesis Based Therapies that optimize stratum corneum and integumentary functions. By focusing on and protecting and supporting the stratum corneum (the outer layer of the epidermis) and supporting the natural physiological functions of the integumentary system (the organ system that consists of the skin, hair, nails, and exocrine glands), we have developed what we believe to represent a new, advanced therapeutic class of therapies capable of unlocking pathways to address emerging gaps in global health.

To learn more about Avadim Technologies, Inc., visit

No comments: